EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Optimizing preclinical models of ageing for translation to clinical trials

Sarah J Mitchell iD, Michael R MacArthur iD, Alice E Kane iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.15902 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sarah J Mitchell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Princeton Branch, Princeton University, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Aging, Translational Research, Biomedical, Drug Evaluation, Preclinical. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, National Institute of Aging, Ludwig Princeton Branch Princeton University and Foundation for Prader Willi Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical models have been the backbone of translational research for more than a century. Rats and mice are critical models in the preliminary stages of drug testing, both for determining efficacy and ruling out potential human‐relevant toxicities. Historically, most preclinical pharmacological studies have used young, relatively healthy, inbred male models in highly controlled environments. In the field of geriatric pharmacology, there is a growing focus on the importance of using more appropriate preclinical models both in the testing of therapeutics commonly used in older populations, and in the evaluation of potential geroprotective drug candidates. Here we provide a commentary on optimizing preclinical models of ageing for translation to clinical trials. We will discuss approaches to modelling clinically relevant contexts such as age, sex, genetic diversity, exposures and environment, as well as measures of clinically relevant outcomes such as frailty and healthspan. We will identify the strengths and limitations of these approaches and areas for improvement. We will also briefly cover new preclinical models that move beyond rodents. We hope this commentary will be a springboard for larger discussions on optimizing preclinical ageing models for testing therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgingTranslational Research, BiomedicalDrug Evaluation, PreclinicalAnimalsHumansClinical Trials as TopicRatsMiceMaleModels, AnimalFemale

Stichwörter der Autor:innen

Caenorhabditis elegansfrailtygerosciencehealthspankillifishmouse modelspolypharmacy

Autor:innen und Institutionen

  • Ludwig Princeton Branch, Princeton University, Princeton, New Jersey, USA.
  • Lewis-Sigler Institute, Princeton University, Princeton, New Jersey, USA.
  • Institute for Systems Biology, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Sarah J Mitchell, Michael R MacArthur, Alice E Kane

Förderung

  • NIA NIH HHS
  • National Institute of Aging
  • Ludwig Princeton Branch Princeton University and Foundation for Prader Willi Research
  • Lewi-Sigler Scholars Program, Princeton University

Zitieren

APA

Mitchell, S. J., MacArthur, M. R., & Kane, A. E. (2025). Optimizing preclinical models of ageing for translation to clinical trials. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15902

Vancouver

Mitchell SJ, MacArthur MR, Kane AE. Optimizing preclinical models of ageing for translation to clinical trials. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.15902

BibTeX
@article{Mitchell2025,
  author = {Mitchell, Sarah J and MacArthur, Michael R and Kane, Alice E},
  title = {Optimizing preclinical models of ageing for translation to clinical trials},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.15902}
}
Kostenlos starten →